313PGenome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
Walsh, N, Furney, S J, Quinn, C, Gullo, G, Crown, JVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz242.008
Date:
October, 2019
File:
PDF, 78 KB
2019